Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Sacituzumab Govitecan in Metastatic Solid Tumors
2019-000579-18Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in Non-hematologic malignancy and Metastatic solid neoplasm, sponsored by Gilead Sciences. Primary endpoint: Objective response rate (ORR) by investigator. Started Mar 2022; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
Non-hematologic malignancyMetastatic solid neoplasm
Beyond the preview
Go deeper on 2019-000579-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000579-18.